CRPS-1 Patients Gain Hope as $150M Merger Advances Neridronate

For pain specialists and health systems, the lack of an FDA-approved therapy for CRPS-1 has left 65,000 newly diagnosed U.S. patients per year with off-label or inadequate options. The Werewolf-Ambros merger directs $150 million in new capital to neridronate, a drug already used in roughly 600,000 patients in Italy, now entering a definitive U.S. Phase 3 trial. If successful, this could create the first disease-specific pharmacotherapy for a costly, hard-to-treat chronic pain syndrome.

On August 21, 2026, Werewolf Therapeutics announced a definitive all-stock merger with privately held Ambros Therapeutics, a transaction that will refocus the Nasdaq-listed entity on neridronate, an investigational bisphosphonate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The combined company will operate under the Ambros Therapeutics name and is expected to trade under the ticker AMBX. Simultaneously, the parties disclosed an oversubscribed $150 million private placement co-led by RA Capital Management and Janus Henderson Investors. The announcement triggered a 1,431.19% pre-market surge in Werewolf shares, although such extreme moves in thinly traded small-cap biotechs often compress when regular trading begins and should be read as a signal of investor enthusiasm rather than a stable valuation anchor.

“

The proposed transaction implies a $500 million valuation for Ambros and approximately $47.5 million for Werewolf before the private placement.

The proposed transaction implies a $500 million valuation for Ambros and approximately $47.5 million for Werewolf before the private placement. That split makes clear this is effectively Ambros becoming public through Werewolf's existing listing; Ambros equity holders will own the overwhelming majority of the combined company. For existing Werewolf shareholders, the deal provides exposure to a later-stage pain asset but also significant dilution. The private placement adds $150 million in new capital, which will further dilute pre-existing holders but extends the runway through pivotal data and regulatory submission.

The clinical thesis centers on neridronate, already approved in Italy for CRPS, osteogenesis imperfecta, and Paget's disease, with roughly 600,000 patients treated. In the United States, there is no FDA-approved therapy specifically for CRPS-1, a condition with an estimated 65,000 newly diagnosed patients each year. Neridronate holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, which could accelerate review and provide market exclusivity if approved. The key test is CRPS-RISE, a randomized, triple-blind Phase 3 trial in warm CRPS-1 that expects to enroll approximately 270 patients, with the primary endpoint focused on change in pain intensity through Week 12. Ambros expects to report topline results in 2028 and believes a successful single pivotal trial could potentially support FDA approval.

The $150 million private placement is expected to fund operations through CRPS-RISE topline results, a planned New Drug Application (NDA) submission, and into the first half of 2029. That is a meaningful derisking event for a development-stage biotech because it removes near-term capital-raising pressure and aligns investors with binary clinical catalysts. Oversubscription and participation by RA Capital and Janus Henderson, both experienced healthcare investors, lend credibility, though financing terms were not fully disclosed.